News & Events
ChemGenex, Hospira, Announce Agreement to License, Develop and Commercialize Leukemia Drug in Europe
18 / 12 / 2009
ChemGenex??s Omapro? Featured During ASH Oral Session
09 / 12 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro? (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors (TKI). New data were presented at the 51st Annual American Society of Hematology Meeting in New Orleans, Louisiana.
Pivotal Data on ChemGenex??s Omapro? Highlighted at ASH Press Conference
07 / 12 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today updated clinical data showing that Omapro? (omacetaxine mepesuccinate) produced durable hematologic and cytogenetic responses in chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. New data was presented at a pre-conference press showcase at the 51st Annual American Society of Hematology Annual Meeting in New Orleans, Louisiana.
ChemGenex to Present Positive Data for Omapro? from Multiple Clinical Trials at ASH
01 / 12 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that updated clinical data from several of its clinical trials with Omapro? (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.
Chairman??s Address for ChemGenex Pharmaceuticals Limited Annual General Meeting
30 / 11 / 2009
The last twelve months have been truly transformational for ChemGenex and we sit now with the possibility of drug approvals in the world??s two largest pharmaceutical markets, the USA and Europe, and the potential launch of Omapro by our own commercial team in the USA next year.
ChemGenex??s Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Agency
27 / 11 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid...
LEO Pharma Completes Peplin Acquisition; Peplin to Continue as an Independent Subsidiary
12 / 11 / 2009
Peplin, Inc. (ASX:PLI) today announced that it has completed its merger with LEO Pharma A/S (LEO) after obtaining the approval of the majority of Peplin stockholders. The deal was originally announced on 3 September, 2009 when LEO, a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, agreed to acquire all outstanding securities of Peplin for approximately US$287.5 million in cash. The merger consideration will be distributed to holders of common stock and CDIs promptly.
Verva Announces Appointment of Professor Michael Cowley to its Board of Directors
11 / 11 / 2009
Verva Pharmaceuticals Ltd. today announced that Professor. Michael A. Cowley, Director of the Monash Obesity & Diabetes Institute, has joined the Company's Board as a non-executive Director. Professor Cowley is a Victorian Endowment for Science, Knowledge and Innovation (VESKI) Innovation Fellow and a Pfizer Senior Research Fellow for 2009. Recently Professor Cowley was awarded the prestigious Commonwealth Science Minister's Prize for Life Scientist of the Year.
ChemGenex Announces FDA Accepts NDA for Omapro? (Omacetaxine Mepesuccinate) and Grants the Filing Priority Review Status
10 / 11 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the U.S. Food & Drug Administration (FDA) has accepted the company??s New Drug Application (NDA) for Omapro? (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation. The NDA has also been granted Priority Review. A Priority Review designation is given to drugs that offer ...
WOMEN??S SEXUAL HEALTH COMPANY CHANGES NAME IN PREPARATION FOR MARKET ENTRY TivaMed Becomes Viveve
09 / 11 / 2009
Women??s sexual health company, TivaMed, today announced it has changed its name to Viveve as it prepares for a 2010 launch of its Viveve system to OB/GYNs in select U.S. markets.
Sunshine Heart - Retirement and Appointment of Director
03 / 11 / 2009
Sunshine Heart, Inc (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announces the retirement of Mr Don Rohrbaugh as a director of the Company effective 31 October 2009. The company further announces the appointment of Mr David Rosa as a director of the Company effective 1 November 2009.
ChemGenex CEO Receives AusBiotech Award
28 / 10 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) is pleased to announce Chief Executive Officer and Managing Director Greg Collier, PhD. was recognized this morning for his outstanding contribution to the advancement of biotechnology in Australia.
KaloBios?? KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients
15 / 10 / 2009
Phase 1/2 clinical trial results with KB001, a Humaneered?, high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in cystic fibrosis patients showed an acceptable safety profile as well as trends toward reducing tissue inflammation and clearance of the bacterium. Results of the multi-center, randomized, double-blind, single-dose, placebo-controlled study are being presented ...
Novasys - Renessa® Treatment for Female Incontinence Named Most Promising New Product Award Presented at Phoenix Conference of Medical Device CEOs
13 / 10 / 2009
NEWARK, CALIF., October 13, 2009 ?? Novasys Medical, Inc., a developer of innovative therapies in women??s health, announced today that its Renessa® non-surgical treatment for female stress urinary incontinence (SUI) was inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product at the Phoenix Medical Device and Diagnostic Conference for Chief Executive Officers.
Sunshine Heart - C-Pulse US Clinical Update Highlights Well Being of Four Initial Clinical Trial Patients
21 / 09 / 2009
Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies, announced today an update on the first four patients implanted with the C-Pulse device at The Ohio State University Medical Center in Columbus, Ohio and Jewish Hospital in Louisville, Kentucky.
ChemGenex Submits New Drug Application for OMAPRO? (Omacetaxine Mepesuccinate) to U.S. FDA
09 / 09 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO? (omacetaxine mepesuccinate). OMAPRO? is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
ChemGenex to Present at Rodman & Renshaw Global Investment Conference in the U.S.
09 / 09 / 2009
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that Greg Collier, PhD, Chief Executive Officer and Managing Director will present a company update
Peplin - LEO Pharma to Acquire Peplin for US$287.5m
03 / 09 / 2009
Peplin, Inc. (ASX:PLI) today announced a definitive merger agreement whereby LEO Pharma A/S (LEO), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will acquire all outstanding securities of Peplin for approximately US$287.5 million (currently A$348.4 million) in cash. This represents a purchase price of US$16.99 per common share of Peplin stock or A$1.03 per Peplin CHESS Depositary Interest (CDI).1
GBS Portfolio Company Peplin Inc To Be Acquired by Leo Pharma for US$287.5m
03 / 09 / 2009
Peplin Inc (ASX:PLI), a clinical stage dermatology company, today announced a definitive agreement whereby Leo Pharma A/S (Leo), a privately-held, leading global pharmaceutical company within Dermatology and Critical Care, will, subject to shareholder approval and other closing conditions, acquire all outstanding securities of Peplin.
Novasys - Renessa® Treatment for Female Incontinence Gets Expanded Medicare Coverage
01 / 09 / 2009
Novasys Medical, Inc., a developer of innovative therapies in women??s health, announced today that Palmetto GBA and TrailBlazer Health Enterprises, LLC---- two large regional Medicare carriers serving over 10.2 million beneficiaries in California, Nevada, Hawaii, Texas, Oklahoma, Colorado, New Mexico and Virginia-----have agreed to cover the Renessa® treatment for female SUI (stress urinary incontinence) in appropriately selected patients with documented medical necessity.
Verva Announces License of Key FGFR Intellectual Property to Isis Pharmaceuticals, Inc. for the Treatment of Obesity and Other Diseases
20 / 08 / 2009
Verva Pharmaceuticals Ltd. and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced the completion of an agreement providing Isis an exclusive license to Verva's intellectual property rights targeting the Fibroblast Growth Factor Receptor (FGFR) with antisense technology for the treatment of diseases, including obesity and other metabolic disorders. Isis also obtains a right of first refusal to license Verva's intellectual property rights targeting FGFR with mechanisms other than antisense, such as small molecule and antibody technologies. Verva received an undisclosed upfront payment and is eligible for future milestone payments and royalties.....
Dr Julie Cherrington Joins Xenome Board
11 / 08 / 2009
Xenome Limited (??Xenome?) today announced that Dr Julie Cherrington has joined the Xenome Board as an independent, Non-Executive Director....
Sunshine Heart - First Female Patients in US Implanted with C-Pulse
10 / 08 / 2009
Sunshine Heart, Inc. (ASX: SHC), a global medical device company focused on innovative technologies for advanced heart failure, announced today that Jewish Hospital in Louisville, Kentucky has completed implants of the Company??s C- PulseTM heart assist system in two female patients, ages fifty-eight and fifty-five, respectively, under a clinical trial approved by the US Food and Drug Administration (FDA). These procedures mark the first US female patients and the third and fourth patients treated with the C-Pulse heart assist system...